With rising Nontuberculous Mycobacteria (NTM) incidence rates and a lack of effective diagnostic tests, vaccines and immunotherapies, pulmonary NTM disease is of increasing concern worldwide.

In support of the search for new therapies for NTM diseases, Johnson & Johnson Innovation is proud to announce that Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has entered into a research collaboration with clinical-stage biopharmaceutical company and Johnson & Johnson Innovation – JLABS @ Shanghai resident company, TenNor Therapeutics (Suzhou) Limited.

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222044/

About TenNor Therapeutics

TenNor Therapeutics (6872.HK), incorporated in 2013, is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of June 30, 2026, TenNor Therapeutics had built a pipeline of eight innovative programs, including two Core Products, namely: rifasutenizol (TNP-2198), a multi-targeted conjugated new molecular entity (“NME”) candidate for the treatment of Helicobacter pylori infection when used in combination with amoxicillin and a proton pump inhibitor, as well as monotherapy for bacterial vaginosis and Clostridioides difficile (C. difficile) infection; and rifaquizinone (TNP-2092) injection, a triple-targeting NME candidate for the treatment of acute bacterial skin and skin structure infection and implant-associated bacterial infections (such as prosthetic joint infection, left ventricular assist device infection and catheter-related bloodstream infection).

For more information, please visit: www.tennortherapeutics.com